Mostrar el registro sencillo del ítem

dc.contributor.authorBatista-Duharte, Alexander
dc.contributor.authorHassouneh, Fakhri
dc.contributor.authorÁlvarez-Heredia, Pablo
dc.contributor.authorPera, Alejandra
dc.contributor.authorSolana Lara, Rafael
dc.date.accessioned2022-09-05T10:42:34Z
dc.date.available2022-09-05T10:42:34Z
dc.date.issued2022
dc.identifier.urihttp://hdl.handle.net/10396/23831
dc.description.abstractIn recent years, the use of immune checkpoint inhibitors (ICIs) in combination with approved or experimental vaccines has proven to be a promising approach to improve vaccine immunogenicity and efficacy. This strategy seeks to overcome the immunosuppressive mechanisms associated with the vaccine response, thereby achieving increased immunogenicity and efficacy. Most of the information on the use of ICIs combined with vaccines derives from studies on certain anti-tumor vaccines combined with monoclonal antibodies (mAbs) against either cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed death-ligand 1 (PD-L1). However, over the past few years, emerging strategies to use new-generation ICIs as molecular adjuvants are paving the way for future advances in vaccine research. Here, we review the current state and future directions of the use of ICIs in experimental and clinical settings, including mAbs and alternative new approaches using antisense oligonucleotides (ASOs), small non-coding RNAs, aptamers, peptides, and other small molecules for improving vaccine efficacy. The scope of this review mainly includes the use of ICIs in therapeutic antitumor vaccines, although recent research on anti-infective vaccines will also be addressed.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightshttps://creativecommons.org/licenses/by/4.0/es_ES
dc.sourcePharmaceutics 14(8), 1721 (2022)es_ES
dc.subjectImmune checkpoint inhibitorses_ES
dc.subjectMolecular adjuvantses_ES
dc.subjectVaccineses_ES
dc.subjectMonoclonal antibodieses_ES
dc.subjectAntisense oligonucleotideses_ES
dc.subjectAptamerses_ES
dc.subjectPeptideses_ES
dc.subjectCTLA-4es_ES
dc.subjectPD-1es_ES
dc.subjectPD-L1es_ES
dc.titleImmune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approacheses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.3390/pharmaceutics14081721es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/847468 (P2Med)es_ES
dc.relation.projectIDJunta de Andalucía. DOC_01421es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem